Evidence-based GLP-1 and peptide science.

Is Retatrutide Safe? Risk Assessment & Long-Term Safety Profile

Retatrutide safety profile from the TRIUMPH trials — what the data shows on serious adverse events, long-term risks, and discontinuation.

Retatrutide Mechanism of Action: How the Triple Agonist Works

How retatrutides triple-receptor mechanism — GLP-1, GIP, and glucagon agonism — produces 4–8% more weight loss than tirzepatide.

Oral Retatrutide: Pills, Drops & Why Injection Is Still Standard

Why oral retatrutide pills and drops sold today arent validated — and what an FDA-approved oral form would actually require.

Retatrutide Phase 3 NEJM: Reading the TRIUMPH Trial Data

Retatrutide Phase 3 TRIUMPH-4 results in plain English — and how to read the upcoming NEJM publication.

Retatrutide Reconstitution Kits: Whats Inside & Where to Get One

What you actually get in a retatrutide kit — and whether buying the kit beats sourcing components separately.

Retatrutide on Reddit: What r/Retatrutide Says About Side Effects, Dosing & Results

Aggregate signal from r/Retatrutide and adjacent subs — how community reports compare to Phase 3 trial data.

Survodutide vs Retatrutide: The Other Triple-Receptor Story

How survodutide (dual agonist) compares to retatrutide (triple agonist) on weight loss, side effects, and MASH liver disease.

Can GLP-1 Cause Depression? What the FDA, EMA, and Large Cohorts Actually Found

An EMA signal in July 2023 raised the alarm. The big follow-up studies, including a 240,000-patient EHR analysis showing semaglutide cut suicidal ideation risk by 73%, told a different story. Here is the honest read.

Can GLP-1 Cause Pancreatitis? An Honest Look at the 2026 Evidence

Trial data shows pancreatitis is rare on GLP-1s — roughly 0.3–0.4% of patients, similar to placebo in most studies. But the signal is real in some analyses, especially with gallstones and rapid weight loss. Here is the per-drug picture, the meta-analysis findings, and what to watch for.

GLP-1 and Thyroid Cancer: The Boxed Warning, the Rat Study, and What the Human Data Actually Show (2026)

Every GLP-1 carries an FDA boxed warning for medullary thyroid carcinoma. The warning came from rat studies. Large human cohort studies — 92,000+ GLP-1 users vs 2.4 million controls — have not confirmed the signal. Here is the full picture.

GLP-1 and the Gallbladder: Stone Risk, Symptoms, and What Changes If You've Had Yours Removed

Semaglutide raises gallbladder disorders to 2.6% vs 1.2% on placebo, and the JAMA meta-analysis of 76 trials puts the weight-loss-dose relative risk at 2.29. Two mechanisms collide: GLP-1 suppresses the cholecystokinin signal that empties the gallbladder, and rapid weight loss supersaturates bile with cholesterol. Here is what changes if you still have your gallbladder, and what changes if you don't.

GLP-1 and Gastroparesis: What the Evidence Actually Shows in 2026

Gastroparesis is the most-litigated GLP-1 complication. The 2025 cohort data shows a 3.3–6.1× relative risk in obesity patients and a 3.67× relative risk in T2D — but absolute incidence is under 1%, and most cases resolve after stopping. Here is the full clinical picture.

Rybelsus Guide: Oral Semaglutide for Type 2 Diabetes (2026)

Rybelsus is the only FDA-approved GLP-1 pill for type 2 diabetes — 3, 7, and 14 mg daily doses, strict empty-stomach rule, A1C drops of 1.0-1.5%, and a $1,027.51 monthly list price. Here is what the PIONEER trials, SNAC absorption, and real-world use actually show.

Trulicity Guide: Weekly Dulaglutide for Type 2 Diabetes (2026)

Trulicity (dulaglutide) is Eli Lilly's once-weekly GLP-1 injection, approved in 2014 for type 2 diabetes. Doses run 0.75 to 4.5 mg, the REWIND trial showed a 12% MACE reduction, and the list price sits near $887 per month. Here is the full breakdown.

Victoza Guide: Daily Liraglutide for Type 2 Diabetes (2026)

Victoza (liraglutide) is the original daily GLP-1 injection for type 2 diabetes — approved in 2010, doses of 0.6/1.2/1.8 mg, A1C drops of 1.0-1.5%, and the LEADER trial cardiovascular benefit. With generic liraglutide now available in 2026, this drug has a fresh second life.

GLP-1 Insurance Coverage 2026: Medicare Bridge, Medicaid by State, Savings Cards, FSA/HSA

How to actually get Wegovy or Zepbound covered in 2026. Commercial copay cards to $25, the new Medicare GLP-1 Bridge at $50/month starting July 2026, Medicaid coverage in 13 states, FSA/HSA rules, prior auth, and how to appeal a denial.

GLP-1 at Costco, CVS, Walmart, and Walgreens: A 2026 Pharmacy Pricing Map

Where to physically fill a Wegovy, Ozempic, or Zepbound prescription in 2026 — cash prices, member programs, retail clinic visits, and manufacturer-direct pickup compared across the major chains.

GLP-1 and Pregnancy: Washout Timing, Breastfeeding, and Unintended Exposure (2026)

Semaglutide and tirzepatide are contraindicated in pregnancy. Here is the exact washout period before conception, what to do if pregnancy happens unexpectedly, what current data show about birth defects, and how breastfeeding guidance differs between injection and oral forms.

Ryan MacielMay 16, 2026